Compare Vaxcyte Inc. Common Stock (PCVX) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs SAP SE — how do they compare? Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.51B), while SAP SE trades at $222.88 (market cap $254.11B). The key difference: SAP SE is far larger — about 24.2× Vaxcyte Inc. Common Stock's market cap, and SAP SE pays a 1.33% dividend while Vaxcyte Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and SAP SE for 118 Days on average.
| PCVX | SAP | |
|---|---|---|
Market Cap | $10.51B | $254.11B |
Volume | 2,644,694 | 2,139,071 |
Sector | Health | Technology |
52-Week High | $73.82 | $280.46 |
52-Week Low | $40.32 | $146.38 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $9.14B | $252.86B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SAP trades at $220.49, up 1.21% today, with a bullish technical outlook supported by moving averages and a consensus price target of $253.60. The company reported strong revenue growth to $36.80B in 2025 and a net income margin of 20.41%, though Q2 2026 EPS missed expectations. Recent news highlights AI-driven cloud revenue growth and partnerships, while cash flow trends show variability with a net outflow of $1.39B in 2025.
The stock presents upside potential based on analyst targets and robust fundamentals, but risks include competitive pressures in enterprise software and execution challenges in AI integration. Investors should weigh solid profitability against valuation multiples like a P/E of 29.48, which may limit near-term gains if growth moderates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
